Fintel reports that on March 12, 2025, LifeSci Capital initiated coverage of Monte Rosa Therapeutics (NasdaqGS:GLUE) with a Outperform recommendation. Analyst Price Forecast Suggests 145.23% Upside As ...

MRT-6160 saw success in its safety and tolerability study while MRT-235 fell short in across a number of indications. Credit: Shutterstock / SergeiShimanovich. Monte Rosa Therapeutics has seen good ...

Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a ...

After hours: March 26 at 7:11:08 PM EDT Loading Chart for GLUE ...

Roche seems determined to develop a commanding position in the emerging molecular glue category, signing up to a $2 billion partnership with Monte Rosa Therapeutics that includes a $50 million ...

BOSTON - Monte Rosa Therapeutics , Inc. (NASDAQ:GLUE) reported fourth quarter revenue that significantly exceeded analyst expectations, sending shares up 6.9% in early trading. The clinical-stage ...

Greetings, and welcome to Monte Rosa Therapeutics Conference Call to discuss the company's pipeline updates and clinical results. At this time, all participants are in a listen-only mode.

BOSTON - Monte Rosa Therapeutics , Inc. (NASDAQ:GLUE) reported fourth quarter revenue that significantly exceeded analyst expectations, sending shares up 6.9% in early trading. The clinical-stage ...